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Mutations in MECOM, Encoding Oncoprotein EVI1,
Cause Radioulnar Synostosis
with Amegakaryocytic Thrombocytopenia
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Radioulnar synostosis with amegakaryocytic thrombocytopenia (RUSAT) is an inherited bone marrow failure syndrome, characterized
by thrombocytopenia and congenital fusion of the radius and ulna. A heterozygous HOXA11 mutation has been identified in two un-
related families as a cause of RUSAT. However,HOXA11mutations are absent in a number of individuals with RUSAT, which suggests that
other genetic loci contribute to RUSAT. In the current study, we performed whole exome sequencing in an individual with RUSAT and
her healthy parents and identified a de novo missense mutation inMECOM, encoding EVI1, in the individual with RUSAT. Subsequent
analysis ofMECOM in two other individuals with RUSAT revealed two additional missense mutations. These three mutations were clus-
tered within the 8th zinc finger motif of the C-terminal zinc finger domain of EVI1. Chromatin immunoprecipitation and qPCR assays of
the regions harboring the ETS-like motif that is known as an EVI1 binding site showed a reduction in immunoprecipitated DNA for
two EVI1 mutants compared with wild-type EVI1. Furthermore, reporter assays showed that MECOM mutations led to alterations in
both AP-1- and TGF-b-mediated transcriptional responses. These functional assays suggest that transcriptional dysregulation by mutant
EVI1 could be associated with the development of RUSAT. We report missense mutations in MECOM resulting in a Mendelian disorder
that provide compelling evidence for the critical role of EVI1 in normal hematopoiesis and in the development of forelimbs and fingers
in humans.Radioulnar synostosis with amegakaryocytic thrombocy-
topenia (RUSAT [MIM: 605432]) is an inherited bone
marrow failure syndrome with skeletal anomalies.1 RUSAT
is characterized by thrombocytopenia that progresses to
pancytopenia and congenital proximal fusion of the radius
and ulna that results in extremely limited pronation and
supination of the forearm. A heterozygous HOXA11
(MIM: 142958) mutation has been identified by candidate
gene analysis in two unrelated families as a cause of
RUSAT.2 However, a number of individuals with RUSAT
lacking HOXA11 mutations have been reported,3 which
suggests that additional genetic loci are responsible for
RUSAT.
To discover a causative mutation, we performed whole
exome sequencing on a girl with RUSAT (TRS1) who lacked
a HOXA11 mutation (Table 1, Figure 1A, Supplemental
Note) and whose parents lacked clinical symptoms of
RUSAT. TRS1 underwent cord blood transplantation
(CBT) at 4 months of age and complete donor-typed
chimerism was confirmed by analysis of her peripheral
blood at day þ35. Donor-derived DNA was sometimes
observed in recipient fingernails and saliva after hemato-
poietic stem cell transplantation.6,7 Therefore, DNA from
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was approved by the Ethics Committee of the Tohoku Uni-
versity School of Medicine. All samples analyzed in this
study were collected after written informed consent was
obtained. We searched for de novo variants as pathogenic
candidates by the filtering steps detailed in Table S1 and
identified one heterozygous alteration, c.2266A>G
in MECOM (EVI1) (GenBank: NM_001105078, MIM:
165215), which resulted in the amino acid substitution
p.Thr756Ala. To confirm that this alteration was a germ-
line variant, Sanger sequencing was performed on DNA
from other tissues via a previously described protocol.8
The c.2266A>G variant was present in a buccal swab, fin-
gernails, and hairs of the girl collected after cord blood
transplantation, but it was absent in blood samples of
her parents and her healthy brother (Figure 1B). We
confirmed high levels of donor chimerism in the nail of
TRS1 (data not shown); therefore, the small mutant allele
fractions from the nails, and possibly the buccal swab,
would be mainly due to her chimerism, rather than
somatic mosaicism. Mutation analysis of all coding exons
and neighboring introns of MECOM in two additional
individuals with simplex RUSAT lacking a HOXA11 muta-
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Table 1. Clinical Manifestations in Individuals with Mutations in MECOM
Individual TRS1 TRS24 TRS35
Clinical Information
Family history simplex simplex simplex
Gender female female male
Age at last clinical examination 3 years 2 months 8 years 9 months 8 years 0 months
Height (SD) 90.3 cm (0.95) 113.7 cm (2.5) 112 cm (2.42)
Weight (SD) 11.8 kg (1.07) 16.6 kg (2.1) 17.8 kg (1.63)
Gestational age 35 weeks 37 weeks 31 weeks
Birth weight 2,160 g 2,058 g 2,180 g
Leukocyte count at birth 6,780/ml 17,100/ml 3,220/ml
Hemoglobin count at birth 4.0 g/dl 12.9 g/dl 2.7 g/dl
Platelet count at birth 5,000/ml 8,000/ml 89,000/ml
Initial clinical presentation neonatal asphyxia systemic petechiae fetal hydrops
HSC transplantation CBT, 4 months uBMT, 18 months uBMT, 8 months
Radioulnar synostosis blt blt blt
Finger abnormality blt bony defect of the
intermediate phalanges
of the fifth digits, blt
brachymesophalangia
of the fourth digits
blt clinodactyly of the
fifth digits
overlapping fingers without
abnormalities of bone
Hearing normal sensorineural hearing
impairment: Rt 55 dB, Lt 33.75 dB
prelingual sensorineural hearing
impairment: Rt 60 dB, Lt 25 dB
Psychomotor development normal normal mild intellectual disability (IQ 67)
Other none cleft palate, dysarthria hydrocele testicle
Mutations in MECOM
cDNA (GenBank:
NM_001105078)
c.2266A>G c.2252A>G c.2248C>T
Protein (GenBank:
NP_001098548)
p.Thr756Ala p.His751Arg p.Arg750Trp
Abbreviations are as follows: HSC, hematopoietic stem cell; CBT, cord blood transplantation; blt, bilateral; uBMT, unrelated bone marrow transplantation; Rt,
right; Lt, left; IQ, intelligence quotient.in individual TRS24 and c.2248C>T (p.Arg750Trp) in
TRS35 (Table 1, Figures 1C and 1D). The c.2252A>G
(p.His751Arg) variant was present in the DNA collected
from a buccal swab and hairs of TRS2 but was absent
from her fingernails and peripheral blood, nor was it
present in her healthy parents. TRS3 presented the
c.2248C>T (p.Arg750Trp) variant in his buccal swab, nails,
and hairs. This variant was not detected in the DNA of his
healthy mother, and the samples of his father were not
available. All of the samples fromTRS2 and TRS3 that we
could analyze were collected after hematopoietic stem
cell transplantation. Therefore, these sequencing results
indicate that the germline mutant allele in the buccal
swab and nails might be diluted by donor-derived DNA.
Alternatively, we could not exclude the possibility for
post-zygotic mutations.9 In total, two of these three vari-
ants were considered to be de novo. All three variants affect
residues in a highly conserved region of EVI1 (Figure 2A)The Americanand were predicted in silico to be damaging (Table S2).
None of the three variants was observed in 382 ethnicity-
matched healthy controls or in public variant databases,
such as dbSNP, 1000 Genomes, the Human Genetic Varia-
tionDatabase, and ExAC (seeWeb Resources). These results
strongly suggest that these variants are disease-causing
mutations.
The Evi1 locus was initially identified as a common
target of the retroviral integration site in murine myeloid
leukemia.10 In humans, MECOM represents a frequent
site of insertional mutagenesis after gene therapy for
X-linked chronic granulomatous disease.11 MECOM
encodes the transcriptional regulator proteins EVI1 and
MDS1-EVI1, which are transcribed from alternative
transcriptional start sites.12 EVI1 has been reported to be
able to recruit either coactivators or corepressors.13 High
MECOM expression, which is observed in 5%–10% of all
cases of acute myeloid leukemia, is predictive of a poorJournal of Human Genetics 97, 848–854, December 3, 2015 849
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Figure 1. Individuals with RUSAT Attrib-
uted to MECOM Mutations
(A) Radiographs of the forearms of TRS1
show bilateral radioulnar synostosis (ar-
rows). Open arrowheads indicate a bilateral
bony defect of the intermediate phalanges
of the fifth digits.
(B–D) Mutation analysis of TRS1 (B), TRS2
(C), and TRS3 (D) and their families.
DNA extraction was performed with a
BuccalAmp DNA Extraction Kit (Epicenter)
for buccal swab and ISOHAIR (Nippon
Gene) for fingernails and hairs. PCR
primers are listed in Table S3. Abb-
reviations are as follows: WT, wild-type;
BMT, bone marrow transplantation; CBT,
cord blood transplantation; NA, not
available.outcome.14 The aberrant expression of MECOM has also
been found in solid tumors, such as ovarian and colon can-
cers.15,16 In inherited bone marrow failure syndromes,
EVI1 is thought to repress RBM8A gene expression by
binding to a site created by a pathogenic variant in the
50 untranslated region of RBM8A in individuals with
thrombocytopenia with absent radii syndrome.17 In
normal human cells,MECOM is expressed in hematopoiet-
ic stem cells and plays an important function in hemato-
poiesis and stem cell self-renewal.14 In mice, Mecom is
expressed at high levels in the urinary system, the lung,
the heart, and the limb bud in embryo,18 which suggests
that this gene plays an important role in limb develop-
ment. These observations support the evidence that
MECOM mutations cause RUSAT.
EVI1 contains seven Cys2His2 zinc finger motifs in its
N-terminal domain that recognize a GATA-like motif850 The American Journal of Human Genetics 97, 848–854, December 3, 2015and three such motifs in its C-termi-
nal domain that recognize an ETS-
like motif19–21 (Figure 2A). In each
zinc finger motif, a zinc ion is tetra-
hedrally coordinated between two
cysteines at one end of the b sheet
and two histidines in the a helix,
which stabilizes protein folding22
(Figure 2B). All three mutations iden-
tified in individuals with RUSAT
affected the histidine essential for
folding stability (Figures S1A and
S1B) or the neighboring residues,
and p.Arg750Trp was located at the
position predicted to contact DNA
directly22 (Figure S1C). These find-
ings suggest that the identified muta-
tions might alter the folding stability
of the 8th zinc finger motif and
the DNA-binding ability of the C-ter-
minal zinc finger domain (ZFD) of
EVI1.To test the DNA binding ability of mutant EVI1 in vivo,
we performed chromatin immunoprecipitation (ChIP)-
qPCR assays on regions known to be EVI1 binding
sites.19 Compared with wild-type EVI1, we observed
significantly reduced levels of RUNX1 exon 1 DNA precip-
itated with p.Arg750Trp and p.His751Arg mutants as well
as reduced levels of CD109 promoter DNA precipitated
with p.Arg750Trp mutants, albeit with large error bars
(Figure S2). These two regions harbor ETS-like motifs
and 12-O-Tetradecanoylphorbol-13-acetate (TPA)-respon-
sive element (TRE) motifs. The TRE motif is commonly
recognized by activator protein-1 (AP-1, formed by JUN
and FOS), and a physical association between EVI1 and
FOS has been reported.19 Our results suggest that the
direct and/or indirect DNA binding ability of two EVI1
mutants to one or more genomic regions might be
decreased.
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Figure 2. Mutations in MECOM Identified in Individuals with RUSAT
(A)MECOMmutations were clustered in the 8th zinc finger motif. All affected residues are completely conserved throughout evolution.
Blue dots indicate the cysteines and histidines essential for the folding stability of the zinc finger domain. A cylinder and open arrows
indicate a helix and b sheets, respectively.
(B) Homology modeling of the 8th zinc finger motif. Homology models of the C-terminal ZFD of EVI1 were generated using SWISS-
MODEL (RRID: nif-0000-03522) on the crystal structure of a designed zinc finger protein bound to DNA (PDB: 1MEY). This protein
and the C-terminal ZFD of the human EVI1 protein share 50% sequence identity.To examine whether EVI1 variants alter transcriptional
regulation, we performed luciferase assays using two
reporter systems, focusing on activator protein-1 (AP-1)
and transforming growth factor b (TGF-b) signaling. First,
we measured luciferase activity upon binding of transcrip-
tion factors to the AP-1 enhancer elements, which is one
of the targets of regulation by EVI1 with dependence
on the C-terminal ZFD.23 Renilla luciferase encoded by
phRLnull-luc was used to normalize the transfection effi-
ciency. We observed a suppression of relative luciferase ac-
tivity (RLA) in cells transfected with wild-type EVI1
compared with cells transfected with empty vector after
treatment with 10% serum, whereas EVI1 mutants dis-
played enhanced suppression—that is, a gain-of-function
effect (Figure 3B). We obtained similar results with
HEK293 cells (data not shown). These results showed
that effects of wild-type EVI1 were different from those
observed in NIH 3T3 cells using a luciferase reporter
plasmid harboring three repeats of TRE followed by the
herpes simplex virus thymidine kinase promoter23 but
were similar to the observations made in an immortalized
normal ovarian epithelial cell line transfected with the
same luciferase reporter plasmid as that used in this
study.25 This discordance might be explained by the differ-
ence of the backbone of each luciferase construct. Next, we
used a p3TP-lux reporter vector, which also contains TRE
and a portion of the plasminogen activator inhibitor
(PAI)-1 promoter24 and has been used to demonstrate
the suppression of TGF-b-mediated transcriptional re-
sponses by EVI1.26 RLA in cells transfected with wild-
type EVI1 was suppressed, unlike cells transfected with
empty vector after treatment with 1 ng/ml TGF-b1,
whereas EVI1 mutants showed an attenuated suppression
effect (Figure 3C). Kurokawa et al. showed that theThe AmericanC-terminal ZFD deletion had a similar effect on TGF-
b-mediated transcriptional response to that of the wild-
type construct.26 Our results raise the possibility that
missense mutations affecting the C-terminal ZFD are also
associated with aberrant TGF-b signaling. These results
indicate that mutations might be gain of function for AP-
1 and partial loss of function for TGF-b signaling. Further
studies are needed to elucidate transcriptional dysregula-
tion in the mutant EVI1 background.
All individuals with mutations in MECOM identified in
this study were simplex cases and required hematopoietic
stem cell transplantation to counter bone marrow failure
(Table 1). By contrast, the individuals with a HOXA11
mutation reported by Thompson et al.1,2 were familial
cases with a broad hematologic spectrum that ranged
from early-onset bone marrow failure to a lack of clinical
problems. Furthermore, TRS1 and TRS3 exhibited severe
anemia at birth (hemoglobin 4.0 and 2.7 g/dl, respec-
tively), whereas the individuals harboring a HOXA11 mu-
tation did not experience this issue. Mutations in MECOM
might therefore be associated with a severe hematologic
phenotype among individuals with RUSAT. Thompson
et al.1 reported an individual with a HOXA11 mutation
who had sensorineural deafness. The two individuals
with MECOM mutations, TRS2 and TRS3, also had senso-
rineural hearing impairments. A mouse model, called
Junbo, expressing a mutation corresponding to human
EVI1 p.Asn782Ile, had susceptibility to otitis media and
hearing loss.27 As for our individuals with RUSAT, TRS3
did not have chronic otitis media, and a past history of
chronic otitis media was uncertain in TRS2. These obser-
vations suggest that individuals with MECOM mutations
would be associated with hearing impairment not due
to chronic otitis media.Journal of Human Genetics 97, 848–854, December 3, 2015 851
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Figure 3. EVI1 Mutants Alter Transcriptional Regulation
(A) Immunoblot of exogenous EVI1 in NIH 3T3 whole-cell lysates.
The protein levels were comparable for FLAG-tagged wild-type and
mutant EVI1.
(B) Luciferase assay for AP-1 enhancer element. Empty or EVI1
expression constructs, pAP-1-luc (Agilent Technologies; contains
seven tandem repeats of TRE-like TGACTAA motif, which is
consensus AP-1 binding site), and phRL null luc (transfection con-
trol) were co-transfected into NIH 3T3 cells using lipofectamine
2000 (Life Technologies). At 18 hr after transfection, the cells
were serum starved in DMEM for 24 hr and were either treated
or untreated with 10% newborn calf serum (GIBCO) for 6 hr after
serum starvation. The bars indicate mean (5SD) fold change rela-
tive to the wild-type (white bar). Experiments were performed in
triplicate and repeated twice. *p < 0.05; **p < 0.01; ***p < 0.001
compared with wild-type.
(C) Luciferase assays using p3TP-lux, which contains three repeats
of TRE fused to a portion of the plasminogen activator inhibitor
(PAI)-1 promoter.24 The cells were treated or untreated with
1 ng/ml human TGF-b1 (Roche Diagnostics) for 6 hr after serum
starvation. The bars indicate mean (5SD) fold change relative to
wild-type (white bar). Experiments were performed in triplicate
and repeated twice. *p < 0.05; **p < 0.01; ***p < 0.001 compared
with wild-type. Statistical analysis was performed with Dunnett’s
test.
Abbreviation is as follows: WT, wild-type.An individual presenting with aplastic anemia and
harboring a null allele28—a de novo 3q26 deletion encom-
passingMECOM—provides important clues to deciphering
the effects of MECOM missense mutations. In a mouse
model, heterozygous knockout ofMecom leads to a marked852 The American Journal of Human Genetics 97, 848–854, Decembimpairment in the self-renewal capacity of long-term he-
matopoietic stem cells due to accelerated differentia-
tion.29 This impairment might occur in the individual
with the 3q26 deletion and possibly in individuals with
RUSAT reported in this study. MECOM haploinsufficiency
might be sufficient to cause bonemarrow failure. However,
no limb anomalies were described in the individual with
the 3q26 deletion,28 which suggests that the missense mu-
tations identified in this study might act as gain-of-func-
tion, partial loss-of-function as shown in Figure 3, or
possibly dominant-negative rather than the complete
loss-of-function mutations affecting the bone develop-
ment of forearms and fingers.
The MECOM mutations identified in this study in indi-
viduals with RUSAT were clustered in the 8th zinc finger
motif in the C-terminal ZFD. The 8th zinc finger motif
is the oligomerization domain involved in interactions
with EVI1 itself and with RUNX1.30 Thus, these mutations
might alter not only protein-DNA binding but also pro-
tein-protein interactions in transcriptional regulation.
Functional interactions between EVI1 and other seq-
uence-specific transcription factors, such as SPI1,31
GATA1,32 SMAD3,26 and FOS,19 have also been reported
previously. In this context, the divergent effect of mutants
observed in luciferase assays in this studymight depend on
altered interaction of mutant EVI1 with DNA and/or other
transcriptional factors. Although knock-in mouse models
harboring mutations in the 8th zinc finger motif of Evi1
have not been reported, Junbo mouse, which had a Evi1
mutation in the 9th zinc finger motif of the same C-termi-
nal ZFD, had extra digits on the forelimbs,27 which sug-
gests an important role for the C-terminal ZFD in digit
development.
In conclusion, we have identified MECOM mutations
in individuals with RUSAT. We report missense muta-
tions in MECOM as a cause of a Mendelian disorder,
although overexpression of MECOM has been shown
to induce myeloid malignancies. Our findings provide
compelling evidence for the critical roles of EVI1 in
normal hematopoiesis and in the development of fore-
limbs and fingers in humans. Further studies are required
to elucidate the mechanisms underlying the develop-
ment of RUSAT.Supplemental Data
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